Business Context and Reporting Period
Company: Moderna, Inc. (MRNA)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Overview: Moderna is a biotechnology company focused on mRNA medicines across four franchises: respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics, and rare disease therapeutics. In 2024, the company transitioned to a multi-product entity with the FDA approval of mRESVIA (RSV vaccine) in May 2024, complementing its primary commercial product, Spikevax (COVID-19 vaccine). The company is navigating a shift from pandemic-era demand to a seasonal, endemic market for respiratory vaccines while advancing a prioritized pipeline of ten potential product approvals over the next three years.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $3,236 | $6,848 | (53)% |
| Net Product Sales | $3,109 | $6,671 | (53)% |
| Cost of Sales | $1,464 | $4,693 | (69)% |
| Gross Margin | 53% | 30% | +23 pts |
| Research & Development (R&D) | $4,543 | $4,845 | (6)% |
| Selling, General & Administrative (SG&A) | $1,174 | $1,549 | (24)% |
| Net Loss | $(3,561) | $(4,714) | (24)% |
| Diluted Loss Per Share | $(9.28) | $(12.33) | (25)% |
| Cash, Cash Equivalents & Investments | $9,519 | $13,281 | (28)% |
| Working Capital | $5,893 | $7,310 | (19)% |
Note: Gross margin improved significantly in 2024 due to reduced inventory write-downs and manufacturing wind-down costs compared to 2023.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 53% to $3.2 billion, driven primarily by a 53% drop in net product sales. This reflects the transition of the COVID-19 vaccine market from pandemic advance purchase agreements to a seasonal commercial model, resulting in lower volumes in Europe and the Rest of World. U.S. sales remained relatively flat year-over-year, aided by a $216 million reversal of prior-year sales provisions.
- Cost Structure Optimization: Cost of sales decreased 69% to $1.5 billion. While absolute costs fell, the cost of sales as a percentage of revenue improved from 70% in 2023 to 47% in 2024. This improvement was driven by a significant reduction in inventory write-downs (from $2.2 billion in 2023 to $495 million in 2024) and lower wind-down costs.
- Expense Reduction: SG&A expenses decreased 24% due to cost-saving initiatives and reduced reliance on external consultants. R&D expenses decreased 6% to $4.5 billion, reflecting reduced spending on clinical trials and manufacturing for specific programs, partially offset by increased personnel costs and the purchase of priority review vouchers.
- Liquidity: Cash and investments decreased by $3.8 billion to $9.5 billion, primarily due to operating cash outflows of $3.0 billion and capital expenditures of $1.1 billion.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Priorities: Management is focused on driving use of Spikevax and mRESVIA, achieving ten product approvals over the next three years, and delivering cost efficiency. The company expects to decrease annual R&D expenses by approximately $1.0 billion by 2027 compared to 2024 levels.
- 2025 Expectations: The company anticipates participating in the full contracting season in the U.S. for both COVID and RSV vaccines in 2025. Product sales are expected to decline further in 2025 due to lower vaccination rates and the fulfillment of advance purchase agreements. Cost of sales as a percentage of revenue is expected to increase in 2025 due to fixed costs being allocated across lower sales volumes.
- Pipeline Milestones: Key upcoming events include PDUFA dates for the next-generation COVID vaccine (May 31, 2025) and the RSV vaccine for high-risk adults 18-59 (June 12, 2025). The company also expects to start registrational studies for rare disease therapeutics (PA and MMA) in 2025.
Risks and Contingencies
- Market Dynamics: Significant uncertainty exists regarding future revenue from COVID and RSV vaccines due to evolving market dynamics, competitive pricing pressure, and public health recommendations. The RSV market was smaller than anticipated in 2024.
- Regulatory and Clinical Risks: The Phase 3 study for the CMV vaccine did not meet early efficacy criteria, though the study continues. The Phase 3 norovirus vaccine trial is on FDA clinical hold following a single adverse event report of Guillain-Barré syndrome.
- Legal Proceedings: The company is involved in patent litigation with Pfizer/BioNTech, GSK, Arbutus, and Northwestern University regarding mRNA and lipid nanoparticle technologies. Additionally, securities class action and derivative litigations were filed in 2024 regarding statements about the RSV vaccine.
- Profitability: The company incurred net losses in 2024 and 2023 and expects to incur additional losses in the future. Long-term sustainable profitability is not guaranteed.
Key Facts for Investor Verification
- Revenue Trajectory: Verify the sustainability of the seasonal COVID vaccine market and the ability to gain market share for mRESVIA against established competitors (Pfizer, GSK).
- Cost Efficiency Execution: Monitor the company's ability to reduce R&D and SG&A expenses as planned to achieve cash breakeven goals, given the projected decline in revenue.
- Pipeline Progress: Track the outcomes of the PDUFA dates for the next-generation COVID vaccine and the RSV vaccine for adults 18-59, as well as the resolution of the clinical hold on the norovirus vaccine.
- Legal Exposure: Assess the potential financial impact of ongoing patent litigation and securities class actions.
- Liquidity Runway: Confirm that the $9.5 billion in cash and investments is sufficient to fund operations through the next 12 months and beyond, considering the continued negative operating cash flow.
